Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory - Episode 5

CAR T and Evolving Treatment Paradigms for Early R/R MM

Panelists discuss the evolution of chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma (R/R MM), the factors that inform its use, and how treatment approaches differ for standard-risk vs functional high-risk patients.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Emerging Updates in Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Discussion of the CEPHEUS Trial.
    EP. 2: Quadruplet Regimens as Front-Line Therapy for Newly Diagnosed Transplant-Ineligible Multiple Myeloma
    EP. 3: Academic Perspectives in Front-Line Treatment Goals in Newly Diagnosed Transplant-Ineligible Multiple Myeloma
    EP. 4: Future Considerations for Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
    Now Viewing
    EP. 5: CAR T and Evolving Treatment Paradigms for Early R/R MM
    EP. 6: Expert Perspectives: Referrals and Present Challenges with CAR T for Early R/R MM
    EP. 7: Optimal Strategies for Bridging Therapy for Patients Receiving CAR T in Early R/R MM
    EP. 8: Cilta-Cel in Early R/R MM: Evolving CAR T Data from CARTITUDE-4
    EP. 9: CAR T in Early R/R MM: Advances in Ide-Cel From the KarMMa-3 Trial
    EP. 10: Weighing CAR T Toxicity Profiles in Early R/R MM
    EP. 11: The Evolving Landscape: CAR T and Future Therapies in Early-Stage R/R Myeloma
    EP. 12: Treatment Overview in Later-Stage Relapsed/Refractory Multiple Myeloma
    EP. 13: Recent Insights Into Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
    EP. 14: Novel Bispecific Antibodies in Development for Relapsed/Refractory Multiple Myeloma
    EP. 15: Future Treatment Considerations for Multiple Myeloma

    Video content above is prompted by the following:

    • How has the use of CAR T evolved for patients with R/R multiple myeloma and what factors inform your practice?
    • Where does CAR T fall in your treatment paradigm? How does your approach differ with patients who are standard risk vs functional high risk?
    x